EUVIMEDEUVIMED entdecken
Crossref

Brain-sensing synNotch–CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models

Senthilnath Lakshmanachetty iD, Milos S Simic iD, Payal B Watchmaker iD, Robert Zhu iD, Takahide Nejo iD, Maggie Colton Cove iD, Jeffrey Haegelin, Haoyu Long iD, Aishi Zhao, Alejandra Bergquist, Wei Yu iD, Brianna Wong und 5 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aed9994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Senthilnath Lakshmanachetty und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Glioma, T-Lymphocytes, Brain Neoplasms, Brain. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse midline glioma (DMG) is a lethal pediatric brain tumor with limited therapeutic options and a poor prognosis. The success of chimeric antigen receptor (CAR) T cell therapy requires both improving T cell tumor infiltration and persistence and reducing the risk of on-target/off-tumor toxicity. Here, we adapted and advanced a brain-restricted CAR T cell platform previously validated in glioblastoma to address the anatomical and biological challenges of DMG. We engineered a T cell circuit in which a brain-specific synthetic Notch (synNotch) receptor recognizing brevican (BCAN) induced CAR expression against EphA2 or IL-13Rα2 (“B-SYNC”), thereby restricting CAR expression to the central nervous system (CNS). In immunodeficient DMG models, a single infusion of intravenous (iv) or intracerebroventricular (icv) B-SYNC circuit T cells led to tumor infiltration, sustained persistence, antitumor activity, and extended survival. An alternative BCAN-primed CAR targeting B7-H3 or IL-13Rα2 (“B-SYNC–B/I”) similarly improved therapeutic efficacy when delivered intravenously. However, icv administration triggered fatal neurotoxicity because of low-level B7-H3 expression in nontumor CNS regions, indicating that rapid CNS exposure via icv delivery can amplify off-tumor toxicity. In contrast, in an immunocompetent syngeneic DMG model, both iv and icv delivery of a murinized BCAN-gated B7-H3 CAR (mB-SYNC–B7-H3) achieved durable tumor clearance and resistance to rechallenge without any detectable neurotoxicity. Mechanistically, synNotch-primed CAR T cells exhibited reduced exhaustion, enhanced activation, and enrichment of naïve and stem cell memory–like subsets. These findings demonstrate that brain-sensing synNotch CAR T circuits represent a generalizable and translatable strategy for targeting multiple CNS malignancies, including DMG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaT-LymphocytesBrain NeoplasmsBrainReceptors, Chimeric AntigenReceptors, NotchImmunotherapy, AdoptiveAnimalsHumansDisease Models, AnimalCell Line, TumorMiceInterleukin-13 Receptor alpha2 Subunit

Substanzen

Receptors, Chimeric AntigenReceptors, NotchInterleukin-13 Receptor alpha2 Subunit

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
  • UCSF Cell Design Institute and Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
  • Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
  • Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.

ORCID-Profile: Senthilnath Lakshmanachetty, Milos S Simic, Payal B Watchmaker, Robert Zhu, Takahide Nejo, Maggie Colton Cove, Haoyu Long, Wei Yu, Ricardo Almeida, Joanna P Phillips, Wendell A Lim, Hideho Okada

Förderung

  • National Institutes of Health

Zitieren

APA

Lakshmanachetty, S., Simic, M. S., Watchmaker, P. B., Zhu, R., Nejo, T., Cove, M. C., Haegelin, J., Long, H., Zhao, A., Bergquist, A., Yu, W., Wong, B., Gallus, M., Almeida, R., Phillips, J. P., Lim, W. A., & Okada, H. (2026). Brain-sensing synNotch–CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aed9994

Vancouver

Lakshmanachetty S, Simic MS, Watchmaker PB, Zhu R, Nejo T, Cove MC, et al. Brain-sensing synNotch–CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aed9994

BibTeX
@article{Lakshmanachetty2026,
  author = {Lakshmanachetty, Senthilnath and Simic, Milos S and Watchmaker, Payal B and Zhu, Robert and Nejo, Takahide and Cove, Maggie Colton and Haegelin, Jeffrey and Long, Haoyu and Zhao, Aishi and Bergquist, Alejandra and Yu, Wei and Wong, Brianna and Gallus, Marco and Almeida, Ricardo and Phillips, Joanna P and Lim, Wendell A and Okada, Hideho},
  title = {Brain-sensing synNotch–CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aed9994}
}
Kostenlos starten →